The role of CDX2 immunohistochemical marker in colorectal adenocarcinoma « CDX2 in colorectal adenocarcinoma »
CDX2 loss is a robust prognostic indicator in CRC, particularly when combined with pT4 stage, highlighting its potential for risk stratification and treatment planning. Larger, prospective studies are needed to standardize CDX2 assessment and validate its clinical utility in colorectal adenocarcinoma.
Authors
- Haifa Rachdi
- Dhouha Bacha (ORCID: https://orcid.org/0000-0002-8430-0072)
- Khadija Bellil (ORCID: https://orcid.org/0009-0003-0181-1155)
- Sarra Ben Rejeb (ORCID: https://orcid.org/0000-0001-9150-3444)
Institutions
- Tunisia Private University (TN)
- Hôpital Mongi Slim (TN)
- Security Forces Hospital (SA)
- Abderrahmane Mami Hospital (TN)
Publication Details
- Journal
- La Tunisie Médicale
- Published
- 2025-12-27
- DOI
- https://doi.org/10.62438/tunismed.v103i10.6093
- Primary Topic
- Digestive system and related health
- Type
- article
- Field-Weighted Citation Impact
- 0.00